Cytosine base editing HBV inibitor therapy(Beam Therapeutics)

N/A

Report date: 2025/03/18 11:34:36

Base Information

Drug NameCytosine base editing HBV inibitor therapy(Beam Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > Base editing
Mechanisms of ActionHBsAg modulators
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBeam Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeam Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A